AR088108A1 - METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA - Google Patents

METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA

Info

Publication number
AR088108A1
AR088108A1 ARP120103680A ARP120103680A AR088108A1 AR 088108 A1 AR088108 A1 AR 088108A1 AR P120103680 A ARP120103680 A AR P120103680A AR P120103680 A ARP120103680 A AR P120103680A AR 088108 A1 AR088108 A1 AR 088108A1
Authority
AR
Argentina
Prior art keywords
aggregates
biological sample
specific antibodies
detecting specific
antibodies
Prior art date
Application number
ARP120103680A
Other languages
English (en)
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of AR088108A1 publication Critical patent/AR088108A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Se divulga un método para detectar anticuerpos específicos Ab en una muestra biológica que comprende los siguientes pasos: poner la muestra en contacto con agregados Ab o con partículas que comprenden superficies similares a los agregados Ab y permitir que los anticuerpos específicos Ab se unan con los agregados Ab, y detectar anticuerpos específicos Ab unidos con los agregados Ab mediante una única técnica de detección de partículas, preferentemente mediante clasificación celular activada por fluorescencia FACS.
ARP120103680A 2011-10-04 2012-10-03 METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA AR088108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11183842.1A EP2579042B1 (en) 2011-10-04 2011-10-04 Method for detecting Aß-specific antibodies in a biological sample

Publications (1)

Publication Number Publication Date
AR088108A1 true AR088108A1 (es) 2014-05-07

Family

ID=46888451

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103680A AR088108A1 (es) 2011-10-04 2012-10-03 METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA

Country Status (24)

Country Link
US (2) US20140234877A1 (es)
EP (3) EP2579042B1 (es)
JP (2) JP6162127B2 (es)
KR (2) KR20140069346A (es)
CN (2) CN103842824A (es)
AR (1) AR088108A1 (es)
AU (2) AU2012320766B2 (es)
BR (2) BR112014008089A2 (es)
CA (2) CA2850840A1 (es)
CY (1) CY1115624T1 (es)
DK (2) DK2579042T3 (es)
ES (2) ES2496341T3 (es)
HK (1) HK1178601A1 (es)
HR (1) HRP20140937T1 (es)
IL (2) IL231057A0 (es)
MX (2) MX2014003983A (es)
PL (2) PL2579042T3 (es)
PT (1) PT2579042E (es)
RS (1) RS53496B1 (es)
RU (2) RU2014117671A (es)
SG (2) SG11201400229XA (es)
SI (1) SI2579042T1 (es)
SM (1) SMT201400145B (es)
WO (2) WO2013050248A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR101658620B1 (ko) * 2014-12-02 2016-09-23 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR101871895B1 (ko) * 2016-04-20 2018-06-28 한국과학기술연구원 응집 단백질의 고감도 광 산화 증폭 면역 분석을 통한 체액기반의 퇴행성 신경질환 진단 방법
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
KR101989383B1 (ko) * 2017-04-04 2019-06-14 조선대학교산학협력단 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브
WO2020045962A1 (ko) * 2018-08-27 2020-03-05 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
KR102108171B1 (ko) * 2018-08-27 2020-05-08 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法
CN113063949A (zh) * 2021-03-23 2021-07-02 中国医学科学院输血研究所 一种血浆中特异性IgM抗体的定量测定方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU8083094A (en) * 1994-10-19 1996-05-15 General Hospital Corporation, The A diagnostic assay for alzheimer's disease: assessment of abeta abnormalities
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
KR100595494B1 (ko) * 2003-02-24 2006-07-03 (주) 디지탈바이오텍 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
TW200700432A (en) * 2005-03-05 2007-01-01 Abbott Gmbh & Co Kg Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
AU2006269405B2 (en) 2005-07-08 2013-01-17 Dsm Ip Assets B.V. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
US7939075B2 (en) * 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies
WO2009051599A1 (en) * 2007-10-19 2009-04-23 The Regents Of The University Of California Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening
US7771957B2 (en) * 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
KR20110036809A (ko) 2008-06-12 2011-04-11 아피리스 아게 파킨슨병과 관련된 증상을 치료하기 위한 화합물
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy

Also Published As

Publication number Publication date
EP2579042B1 (en) 2014-07-09
RU2014117677A (ru) 2015-11-10
MX2014003983A (es) 2014-05-07
CN103842824A (zh) 2014-06-04
SG11201400229XA (en) 2014-05-29
EP2579042A1 (en) 2013-04-10
ES2496341T3 (es) 2014-09-18
PT2579042E (pt) 2014-09-09
RS53496B1 (en) 2015-02-27
CN103842825A (zh) 2014-06-04
CY1115624T1 (el) 2017-01-04
AU2012320766A1 (en) 2014-03-13
HK1178601A1 (en) 2013-09-13
BR112014008088A2 (pt) 2017-04-18
WO2013050249A1 (en) 2013-04-11
PL2764367T3 (pl) 2019-04-30
KR20140069346A (ko) 2014-06-09
US20140234877A1 (en) 2014-08-21
CA2850843A1 (en) 2013-04-11
DK2764367T3 (en) 2018-10-29
JP6162127B2 (ja) 2017-07-12
EP2764367B1 (en) 2018-07-25
DK2579042T3 (da) 2014-07-21
JP2014529087A (ja) 2014-10-30
BR112014008089A2 (pt) 2017-04-18
CN103842825B (zh) 2016-04-20
IL231057A0 (en) 2014-03-31
CA2850840A1 (en) 2013-04-11
KR20140073568A (ko) 2014-06-16
RU2014117671A (ru) 2015-11-10
SG11201400223SA (en) 2014-05-29
JP2014529088A (ja) 2014-10-30
EP2764368A1 (en) 2014-08-13
PL2579042T3 (pl) 2014-12-31
SI2579042T1 (sl) 2014-09-30
SMT201400145B (it) 2014-11-10
IL231620A0 (en) 2014-05-28
US20140242727A1 (en) 2014-08-28
ES2692185T3 (es) 2018-11-30
US9625459B2 (en) 2017-04-18
WO2013050248A1 (en) 2013-04-11
AU2012320767A1 (en) 2014-03-13
MX2014003984A (es) 2014-05-07
EP2764367A1 (en) 2014-08-13
HRP20140937T1 (hr) 2014-12-05
AU2012320766B2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
AR088108A1 (es) METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA
MX2010005571A (es) Articulos y metodos para muestreo ambiental.
WO2013074520A3 (en) Detection, isolation and analysis of rare cells in biological fluids
WO2014152048A3 (en) Assemblies and methods for reducing optical crosstalk in particle processing systems
CL2011002228A1 (es) Aparato para el analisis integrado de acidos nucleicos en tiempo real, y metodo de detecicion de dichas moleculas.
WO2010135574A3 (en) Systems and methods for determining the percentage of glycated hemoglobin
WO2011108909A3 (en) Method and kit for isolating target cell
BRPI1013896A2 (pt) Célula de levedura, e, métodos para produzir um composto isoprenóide e para detectar em uma amostra biológica a presença ou ausência de uma célula microbiana geneticamente.
WO2013050881A3 (en) Direct nucleic acid analysis
WO2009089512A3 (en) Immune system modeling devices and methods
EP2279413A4 (en) PROCEDURE, ANTIBODIES AND KITS FOR DETECTING LIQUOR IN A SAMPLE
WO2009105212A3 (en) Detection of polyomavirus
IN2014DN08957A (es)
WO2012151105A3 (en) Basophil analysis system and method
AU2011285694A8 (en) Detection of degradation products of canine NT-proBNP
EP2431740A4 (en) METHOD FOR MEASURING EQUOL IN A IMMUNO-TEST BIOLOGICAL SAMPLE, NECESSARY FOR MEASUREMENT, AND METHOD FOR DETERMINING EQUOLUTION PRODUCTION CAPACITY OF A SUBJECT
WO2012170206A3 (en) Color-producing diagnostic systems, reagents and methods
WO2011127001A3 (en) Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials
WO2010040108A8 (en) Method for measuring carbon nanotubes taken-up by a plurality of living cells
CL2008001621A1 (es) Metodo para detectar el componente caliqueamicina en un conjugado covalente caliqueamicina-portador en una muestra de fluido, donde la caliqueamicina se detecta luego de romper dicha union, preferentemente por espectrometria de masas; kit para determinar la concentracion de caliqueamicina en una muestra.
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
AR095995A1 (es) MÉTODO PARA DETECTAR ANTICUERPOS ESPECÍFICOS ANTI Ab EN UNA MUESTRA BIOLÓGICA
EP2416159A4 (en) METHOD FOR DETECTING ANTIBODY AGAINST SITH-1 IN A BIOLOGICAL SAMPLE
WO2012151039A3 (en) Compositions and methods for detecting mycobacterium
GB201119585D0 (en) Assay

Legal Events

Date Code Title Description
FB Suspension of granting procedure